We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Types Correlate with Survival After Prostate Cancer Vaccine

By LabMedica International staff writers
Posted on 29 Sep 2015
Print article
Image: Scanning electron micrograph of human prostate cancer cells (Photo courtesy of University of Sheffield).
Image: Scanning electron micrograph of human prostate cancer cells (Photo courtesy of University of Sheffield).
Simple, inexpensive strategies to target treatment to likely responders could substantially improve efficacy while simultaneously reducing health care costs, but identification of reliable biomarkers has proven challenging.

ABO blood type influences numerous aspects of biology and medicine, such as susceptibility to infection by various pathogens and potential for complications due to blood transfusions and while there are a variety of methods for typing patients, standard methods are not ideal for all situations.

Chemical biologists at the National Cancer Institute, National Institutes of Health (Frederick, MD, USA) and their colleagues obtained 220 sera samples consisting of 93 type O individuals, 58 type A individuals, 32 type B individuals, and 37 type AB individuals. All samples were stored at -80 °C or -20 °C until used. Blood type information was available in the clinical records for eight patients with metastatic castration-resistant prostate cancer (mCRPC) who enrolled in a single-center phase II study of a prostate vaccine.

Blood typing methods were developed using the normalized antibody signals to Blood Group A (BG-A) and BG-B antigens. For two component systems, the BG-A and BG-B components were systematically varied to identify optimal pairings. For each component, the signal ranges were partitioned into three groups: positive, negative, and unclassified. The team developed a new glycan microarray-based method for determining ABO blood type. The method requires only 4 μL of serum, provides 97% accuracy, and allows simultaneous profiling of many other serum anti-glycan antibodies. After validation with 220 healthy subjects of known blood type, the method was then applied to 74 PROSTVAC-VF patients and 37 control patients from a phase II trial.

The authors concluded that that type B and O prostate vaccine trial patients demonstrated markedly improved clinical outcomes relative to A and AB patients, including longer median survival, longer median survival relative to Halabi predicted survival, and improved overall survival via Kaplan-Meier survival analysis. Consequently, blood type may provide an inexpensive screen to preselect patients likely to benefit from prostate vaccine therapy. The study was published on August 18, 2015, in the journal Oncotarget.

Related Links:

US National Cancer Institute 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.